PMID- 32218824
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 19
IP  - 4
DP  - 2020 Apr
TI  - miR-939-3p promotes epithelial-mesenchymal transition and may be used as a 
      prognostic marker in hepatocellular carcinoma.
PG  - 2727-2732
LID - 10.3892/ol.2020.11361 [doi]
AB  - Hepatocellular carcinoma (HCC) is one of the most common types of cancer 
      worldwide with a high morbidity and mortality rate. An increasing number of 
      studies have demonstrated that microRNAs (miRNAs) serve an important role in HCC. 
      The present study investigated the role of miR-939-3p in HCC. It was demonstrated 
      that miR-939-3p was upregulated in HCC cell lines and HCC tissues compared with 
      normal liver cell lines and paired normal tissues, respectively. It was also 
      found that upregulation of miR-939-3p expression levels in HCC tissues was 
      associated with a less favorable prognosis. Moreover, the overexpression of 
      miR-939-3p in LM3 cells enhanced the metastatic capacity of these cells and 
      promoted epithelial-mesenchymal transition (EMT). In contrast, miR-939-3p 
      inhibition decreased the invasive capacity of HCC cells and EMT. Potential 
      binding target of miR-939-3p to estrogen receptor 1 (ESR1) were predicted using 
      TargetScan. The expression levels of miR-939-3p were negatively associated with 
      ESR1 in HCC tissues based on data from The Cancer Genome Atlas. A luciferase 
      reporter assay was used to confirm ESR1 as a direct downstream target of 
      miR-393-3p. The miR-939-3p/ESR1 axis may be a potential novel target for the 
      treatment of HCC.
CI  - Copyright: (c) Chen et al.
FAU - Chen, Fei
AU  - Chen F
AD  - Department of Digestive Center, Tiantai Branch of Zhejiang Provincial Peoples' 
      Hospital, Taizhou, Zhejiang 317200, P.R. China.
FAU - Ni, Xiaoying
AU  - Ni X
AD  - Department of Digestive Center, Tiantai Branch of Zhejiang Provincial Peoples' 
      Hospital, Taizhou, Zhejiang 317200, P.R. China.
FAU - Chen, Lingxiu
AU  - Chen L
AD  - Department of Digestive Center, Tiantai Branch of Zhejiang Provincial Peoples' 
      Hospital, Taizhou, Zhejiang 317200, P.R. China.
FAU - Wang, Xiaoyan
AU  - Wang X
AD  - Department of Digestive Center, Tiantai Branch of Zhejiang Provincial Peoples' 
      Hospital, Taizhou, Zhejiang 317200, P.R. China.
FAU - Xu, Ji
AU  - Xu J
AD  - Department of Gastrointestinal and Pancreatic Surgery, Zhejiang Provincial 
      Peoples' Hospital, Hangzhou, Zhejiang 310000, P.R. China.
AD  - Key Laboratory of Gastroenterology of Zhejiang, Peoples' Hospital of Hangzhou 
      Medical College, Hangzhou, Zhejiang 310000, P.R. China.
AD  - School of Clinical Medicine, Peoples' Hospital of Hangzhou Medical College, 
      Hangzhou, Zhejiang 310000, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20200130
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC7068245
OTO - NOTNLM
OT  - estrogen receptor 1
OT  - hepatocellular carcinoma
OT  - microRNA-939-3p
EDAT- 2020/03/29 06:00
MHDA- 2020/03/29 06:01
PMCR- 2020/01/30
CRDT- 2020/03/29 06:00
PHST- 2019/04/16 00:00 [received]
PHST- 2019/12/13 00:00 [accepted]
PHST- 2020/03/29 06:00 [entrez]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2020/03/29 06:01 [medline]
PHST- 2020/01/30 00:00 [pmc-release]
AID - OL-0-0-11361 [pii]
AID - 10.3892/ol.2020.11361 [doi]
PST - ppublish
SO  - Oncol Lett. 2020 Apr;19(4):2727-2732. doi: 10.3892/ol.2020.11361. Epub 2020 Jan 
      30.